Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
St. Jude Comprehensive Cancer Center receives “exceptional” score from National Cancer Institute—highest rating awarded to cancer centers.
St. Jude Children’s Research Hospital -Washington University Pediatric Cancer Genome Project identifies the most common genetic alteration yet in the brain tumor ependymoma; results offer clues for fighting other cancers. (Richard Gilbertson, MD, PhD, David Ellison, MD, PhD, Jinghui Zhang, PhD)
A hunt through billions of pieces of genetic information uncovers new clues on treatments for childhood ependymoma.
Scientists explore subtypes of a deadly brain tumor.
St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project lifts lid on the most aggressive subtype of medulloblastoma and finds genes that cooperate in tumor development. (Dr. Richard Gilbertson)
For many years, St. Jude researchers have been investigating the connection between genetics and pediatric cancer. Those approaches continue to have dramatic implications for clinical care.
Research led by St. Jude Children’s Research Hospital investigators used a pioneering approach to drug development and identified dozens of potential new treatments of ependymoma, a rare tumor of the brain and spinal cord.
Noted researcher will direct the country's only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children.
Sometimes two wrongs do, in fact, make a right
International effort led by St. Jude Children’s Research Hospital scientists is expected to fuel development of targeted therapies and aid the search for unique combinations of cells and mutations that lead to other cancers
Scientists have long recognized that cancers may look the same under the microscope, but carry different mutations, respond differently to treatment and result in vastly different outcomes for patients.
St. Jude scientists have answered a central question in cancer biology: whether normal stem cells can give rise to tumors.
Whenever family and friends are invited to your home, chances are the evening will end with everyone lingering in the kitchen. Perhaps someone has a warm pot of coffee to share, a story or a hearty laugh. Whatever the attraction, the heart of the home beats strongest when everyone joins together. At St. Jude Children’s Research Hospital, the Chemical Biology and Therapeutics (CBT) department serves a similar role.
Richard Gilbertson, MD, PhD, has received almost $1 million in support from two foundations that support brain tumor research.
St. Jude researchers have found a vulnerable spot in brain tumors they are trying to exploit to improve the treatment of these cancers and prevent tumors from returning.
St. Jude researchers launch a counterattack on pediatric cancer using molecular-targeted therapy. As scientists learn more about the human genome and specific genetic mutations, they are finding new strategies to ambush the enemy.
The mouse Brain Gene Expression Map at St. Jude shows where and when genes influence development of the brain and helps researchers study links between gene mutations and cancers.
The discovery that expression of specific genes can accurately report the presence of mutations in biochemical pathways within medulloblastoma cells could speed development of more effective and less toxic treatments.
Thanks to the St. Jude Neurobiology and Brain Tumor Program, victory is within reach for kids with medulloblastoma.
Ependymomas that occur in different parts of the central nervous system appear to arise from different subpopulations of stem cells. The discovery explains why some identical-looking ependymomas are actually distinctly different diseases...
Clinical researchers are getting closer to an international clinical trial to improve guidelines for treatment of medulloblastoma.